4//SEC Filing
Friedberg Ezra M 4
Accession 0001753926-25-001079
CIK 0001919246other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 9:05 PM ET
Size
18.4 KB
Accession
0001753926-25-001079
Insider Transaction Report
Form 4
Friedberg Ezra M
Director
Transactions
- Conversion
Common Stock
2025-07-01$10.00/sh+40,000$400,000→ 40,000 total(indirect: By LLC) - Purchase
Series A Convertible Preferred Stock
2025-07-01+40,000→ 40,000 total(indirect: By LLC)Exercise: $10.00→ Common Stock (92,072 underlying) - Conversion
Common Stock
2025-07-01$10.00/sh+40,000$400,000→ 40,000 total(indirect: By LLC) - Purchase
Series A Convertible Preferred Stock
2025-07-01+40,000→ 40,000 total(indirect: By LLC)Exercise: $10.00→ Common Stock (40,000 underlying) - Conversion
Series A Convertible Preferred Stock
2025-07-01−40,000→ 0 total(indirect: By LLC)Exercise: $10.00→ Common Stock (40,000 underlying) - Conversion
Series A Convertible Preferred Stock
2025-07-01−40,000→ 0 total(indirect: By LLC)Exercise: $10.00→ Common Stock (40,000 underlying)
Holdings
- 54,573
Common Stock
Footnotes (3)
- [F1]The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.
- [F2]Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
- [F3]The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.
Documents
Issuer
Pelthos Therapeutics Inc.
CIK 0001919246
Entity typeother
Related Parties
1- filerCIK 0001679440
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 9:05 PM ET
- Size
- 18.4 KB